Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation.

Abstract:

:We integrated molecular data with available prognostic factors in patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) for myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (sAML) from MDS to evaluate their impact on prognosis. Three hundred four patients were sequenced for mutations in 54 genes. We used a Cox multivariate model and competing risk analysis with internal and cross validation to identify factors prognostic of overall survival (OS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM). In multivariate analysis, mutated NRAS, U2AF1, IDH2, and TP53 and/or a complex karyotype were significant prognostic markers for OS besides age above 60 years, remission status, IPSS-R cytogenetic risk, HCT-CI > 2 and female donor sex. Mutated NRAS, IDH1, EZH2, and TP53 and/or a complex karyotype were genetic aberrations with prognostic impact on CIR. No molecular markers were associated with the risk of NRM. The inclusion of molecular information results in better risk prediction models for OS and CIR when assessed by the Akaike information criterion. Internal cross validation confirmed the robustness of our comprehensive risk model. In summary, we propose to combine molecular, cytogenetic, and patient- and transplantation-associated risk factors into a comprehensive risk model to provide personalized predictions of outcome after alloHCT.

journal_name

Ann Hematol

journal_title

Annals of hematology

authors

Heuser M,Gabdoulline R,Löffeld P,Dobbernack V,Kreimeyer H,Pankratz M,Flintrop M,Liebich A,Klesse S,Panagiota V,Stadler M,Wichmann M,Shahswar R,Platzbecker U,Thiede C,Schroeder T,Kobbe G,Geffers R,Schlegelberger B,Gö

doi

10.1007/s00277-017-3027-5

subject

Has Abstract

pub_date

2017-08-01 00:00:00

pages

1361-1372

issue

8

eissn

0939-5555

issn

1432-0584

pii

10.1007/s00277-017-3027-5

journal_volume

96

pub_type

杂志文章,多中心研究
  • Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.

    abstract::We conducted a phase 2 study with bortezomib, doxorubicin, and dexamethasone (PAD) followed by thalidomide and dexamethasone (TD) in patients with relapsed multiple myeloma (MM). Forty patients were enrolled between November 2005 and October 2007, with follow-up continuing until January 2009. Efficacy could be assesse...

    journal_title:Annals of hematology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00277-010-0943-z

    authors: Lee SS,Suh C,Kim BS,Chung J,Joo YD,Ryoo HM,Do YR,Jin JY,Kang HJ,Lee GW,Lee MH,Shim H,Kim K,Yoon SS,Bang SM,Kim HY,Lee JJ,Park J,Lee DS,Lee JH,Korean Multiple Myeloma Working Party.

    更新日期:2010-09-01 00:00:00

  • Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF.

    abstract::Hematopoietic recovery in 115 patients with metastatic breast cancer or metastatic melanoma, enrolled in phase-I studies of recombinant growth factors while undergoing treatment with high-dose chemotherapy with autologous bone marrow support, was examined with assays of bone marrow progenitor cells and peripheral bloo...

    journal_title:Annals of hematology

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF01696346

    authors: Laughlin MJ,Kirkpatrick G,Sabiston N,Peters W,Kurtzberg J

    更新日期:1993-12-01 00:00:00

  • Regulation of FLT3 and its ligand in normal hematopoietic progenitor cells.

    abstract::FLT3 and its ligand (FL) are one of the regulators of normal hematopoiesis. Ligand-independent activation of FLT3 occurs in about 30% of acute myeloid leukemia cases and is one goal for selectively targeted therapies. However, the function of FLT3/FL in the regulation of non-malignant immature hematopoietic cells is p...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-008-0605-6

    authors: Weisel KC,Yildirim S,Schweikle E,Kanz L,Möhle R

    更新日期:2009-03-01 00:00:00

  • Antiapoptotic effect of interleukin-2 (IL-2) in B-CLL cells with low and high affinity IL-2 receptors.

    abstract::Although B chronic lymphocytic leukemia (B-CLL) cells express the alpha chain of the interleukin-2 (IL-2) receptor CD25, little is known about the effect of IL-2 on apoptosis in B-CLL cells. We have shown previously that stimulation of B-CLL cells with a CpG-oligonucleotide induces IL-2 high affinity receptors. In our...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-010-0994-1

    authors: Decker T,Bogner C,Oelsner M,Peschel C,Ringshausen I

    更新日期:2010-11-01 00:00:00

  • MicroRNAs mark in the MLL-rearranged leukemia.

    abstract::MicroRNAs are short noncoding RNAs, known regulators of several signaling pathways cell differentiation and proliferation, development, and apoptosis, which are deregulated in acute leukemia. Mixed lineage leukemia (MLL) gene encodes a protein with histone methyltransferase activity, which is essential for the fine tu...

    journal_title:Annals of hematology

    pub_type: 杂志文章,评审

    doi:10.1007/s00277-013-1803-4

    authors: Benetatos L,Vartholomatos G

    更新日期:2013-11-01 00:00:00

  • Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients.

    abstract::Although retreatment with alemtuzumab in relapsing B-cell chronic lymphocytic leukemia (CLL) may be beneficial, there has thus far been no thorough analysis available on this topic. Data were collected from 30 chemotherapy-pretreated patients with progressive CLL who had received alemtuzumab twice in consecutive, dist...

    journal_title:Annals of hematology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00277-011-1192-5

    authors: Fiegl M,Falkner F,Steurer M,Zojer N,Hopfinger G,Haslbauer F,Winder G,Voskova D,Andel J,Lang A,Brychtova Y,Mayer J,Greil R,Gastl G,Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia.,Czech Leuk

    更新日期:2011-09-01 00:00:00

  • Distinct clinical and biological characteristics of acute myeloid leukemia with higher expression of long noncoding RNA KIAA0125.

    abstract::Expression of long non-coding RNA KIAA0125 has been incorporated in various gene expression signatures for prognostic prediction in acute myeloid leukemia (AML) patients, yet its functions and clinical significance remain unclear. This study aimed to investigate the clinical and biological characteristics of AML beari...

    journal_title:Annals of hematology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s00277-020-04358-y

    authors: Wang YH,Lin CC,Hsu CL,Hung SY,Yao CY,Lee SH,Tsai CH,Hou HA,Chou WC,Tien HF

    更新日期:2021-02-01 00:00:00

  • Interim PET-CT-guided therapy in elderly patients with Hodgkin lymphoma-a retrospective national multi-center study.

    abstract::Hodgkin lymphoma (HL), a disease of mostly young patients, also peaks in the elderly. Despite the profound improvement in the outcome of young patients, in the elderly, 5-year progression-free survival (PFS) rates are under 70%. Interim PET-CT (iPET) is known to be highly predictive for PFS in young HL patients, but i...

    journal_title:Annals of hematology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s00277-019-03686-y

    authors: Bentur OS,Dann EJ,Paran E,Lavie D,Nachmias B,Ron Y,Dally N,Gutwein O,Herishanu Y,Sarid N,Avivi I,Perry C

    更新日期:2019-07-01 00:00:00

  • Predictors for splenectomy among patients with primary chronic immune thrombocytopenia: a population-based cohort study from Denmark.

    abstract::We conducted a nationwide cohort study of adult Danish patients with primary chronic immune thrombocytopenia (cITP) to examine selected patient and clinical characteristics as predictors for splenectomy. We analyzed data from the Danish National Patient Registry and patient medical records from 1996 to 2007. Using Cox...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-010-1047-5

    authors: Jensen AO,Nørgaard M,Engebjerg MC,Farkas DK,Fryzek JP,Zhao S,Sørensen HT

    更新日期:2011-02-01 00:00:00

  • DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.

    abstract::A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM). Thirty patients were treated with three 21-day cycles of bortezom...

    journal_title:Annals of hematology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s00277-009-0726-6

    authors: Kropff M,Liebisch P,Knop S,Weisel K,Wand H,Gann CN,Berdel WE,Einsele H,Deutsche Studiengruppe Multiples Myelom, DSMM.

    更新日期:2009-11-01 00:00:00

  • The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia.

    abstract::This study aimed to determine the clinical characteristics and prognostic significance of the meningioma 1 (MN1) gene and MN1-associated microRNA expression in Chinese adult de novo acute myeloid leukemia (AML) patients. The expression level of MN1, microRNA-20 (miR-20a), and microRNA-181b (miR-181b) in bone marrow mo...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-013-1729-x

    authors: Xiang L,Li M,Liu Y,Cen J,Chen Z,Zhen X,Xie X,Cao X,Gu W

    更新日期:2013-08-01 00:00:00

  • Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial.

    abstract::The impact of intraocular involvement (IOL) in primary CNS lymphoma (PCNSL) has not been sufficiently evaluated. Here, we present the analysis of IOL in the only completed randomized phase III trial in PCNSL. The G-PCNSL-SG1 study evaluated the role of whole-brain radiotherapy in primary therapy of PCNSL. Data of the ...

    journal_title:Annals of hematology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s00277-014-2212-z

    authors: Kreher S,Strehlow F,Martus P,Roth P,Hertenstein B,Röth A,Birnbaum T,Griesinger F,Rauch M,Kanz L,Thiel E,Weller M,Korfel A

    更新日期:2015-03-01 00:00:00

  • Absolute monocyte count is a predictor of overall survival and progression-free survival in nodal peripheral T cell lymphoma.

    abstract::Nodal peripheral T cell lymphomas (nPTCL) present aggressive clinical course, and its heterogeneous nature and poor prognosis with current therapeutic strategies make it a target for the development of new prognostic markers. Thus, we investigated tumor-associated macrophages (TAM) according to the number of cells exp...

    journal_title:Annals of hematology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s00277-019-03731-w

    authors: de Pádua Covas Lage LA,Hamasaki DT,Moreira FR,Rocha V,Zerbini MCN,Pereira J

    更新日期:2019-09-01 00:00:00

  • Characteristics of pulmonary complications in non-Hodgkin's lymphoma patients treated with rituximab-containing chemotherapy and impact on survival.

    abstract::Patients with non-Hodgkin's lymphoma (NHL) receiving rituximab-containing chemotherapy are at risk of developing respiratory complications, but comprehensive information on these complications and their impact on survival is lacking. We performed a retrospective cohort analysis on 123 NHL patients who received rituxim...

    journal_title:Annals of hematology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s00277-018-3448-9

    authors: Keefer K,Bender R,Liao J,Sivik J,Van de Louw A

    更新日期:2018-12-01 00:00:00

  • Long-term outcome of follicular low-grade lymphoma. A report of 91 patients.

    abstract::We retrospectively analyzed overall survival and survival after progression in 91 patients with low-grade follicular lymphoma (LGFL). Histological subtype was B in 75 patients and C in 16 patients. Twelve patients with localized disease received involved-field radiotherapy; seven patients without bulky disease had no ...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/BF01695972

    authors: Morel P,Dupriez B,Plantier-Colcher I,Gosselin B,Declercq C,Pollet JP,Bauters F

    更新日期:1993-06-01 00:00:00

  • Abnormal depolarizing patterns in three patients with filarial infection.

    abstract::Several authors have described a particular potential of automated depolarization analysis in detecting malaria infection as part of the routine full blood count (FBC) performed by the Cell-Dyn 4000 analyzer. In these cases, abnormal depolarizing patterns are due to the presence of leukocyte-associated malaria hemozoi...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-003-0786-y

    authors: Crespo S,Palacios G,Scott S,Lago M,Puente S,Martínez M,Baquero M,Subirats M

    更新日期:2004-05-01 00:00:00

  • Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a "Watch and wait" strategy after complete resection.

    abstract::Data on clinical features and outcome in pediatric follicular lymphoma (pFL) are scarce. The aim of this retrospective study including 13 EICNHL and/or i-BFM study group members was to assess clinical characteristics and course in a series of 63 pFL patients. pFL was found to be associated with male gender (3:1), olde...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-013-1785-2

    authors: Attarbaschi A,Beishuizen A,Mann G,Rosolen A,Mori T,Uyttebroeck A,Niggli F,Csoka M,Krenova Z,Mellgren K,Kabickova E,Chiang AK,Reiter A,Williams D,Burkhardt B,European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) an

    更新日期:2013-11-01 00:00:00

  • Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival.

    abstract::The aim of the present study was to investigate the prognostic role of pre- and/or early post-autologous stem cell transplantation (ASCT) (18)F-flourodeoxyglucose (FDG) positron emission tomography (PET) in patients with relapsed/refractory Hodgkin lymphoma. Forty-three consecutive patients were enrolled in this study...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-011-1209-0

    authors: Sucak GT,Özkurt ZN,Suyani E,Yaşar DG,Akdemir ÖÜ,Aki Z,Yeğin ZA,Yağci M,Kapucu ÖL

    更新日期:2011-11-01 00:00:00

  • Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.

    abstract::Bortezomib synergizes with melphalan in preclinical and early clinical studies. Updated data from our phase 1/2 study assessing the safety and efficacy of bortezomib plus melphalan in relapsed/refractory multiple myeloma (MM) are presented. Bortezomib (0.7, 1.0, or 1.3 mg/m(2)) on days 1, 4, 8, and 11 and oral melphal...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-008-0501-0

    authors: Berenson JR,Yang HH,Vescio RA,Nassir Y,Mapes R,Lee SP,Wilson J,Yellin O,Morrison B,Hilger J,Swift R

    更新日期:2008-08-01 00:00:00

  • JAK2V617F and calreticulin mutations in recurrent venous thromboembolism: results from the EDITH prospective cohort.

    abstract::Cancer incidence in patients with recurrent unprovoked venous thromboembolism (VTE) is much higher than after a first event, but the incidence of myeloproliferative neoplasms (MPN) in this situation is still unknown. We tested for JAK2V617F and calreticulin mutants, 372 DNA samples of patients treated for (VTR). Among...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-016-2853-1

    authors: Ianotto JC,Chauveau A,Mottier D,Ugo V,Berthou C,Lippert E,Delluc A

    更新日期:2017-03-01 00:00:00

  • Long-term follow-up of rituximab in treatment of chronic graft-versus-host disease-single center experience.

    abstract::Rituximab was recently described also as first-line therapy of chronic graft-versus-host disease (cGvHD). We retrospectively analyzed the efficacy and safety of all patients receiving rituximab for treatment of cGvHD between 2005 and 2016 at the Regensburg University transplant center with a median follow-up after rit...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-019-03768-x

    authors: Klobuch S,Weber D,Holler B,Edinger M,Herr W,Holler E,Wolff D

    更新日期:2019-10-01 00:00:00

  • The effect of gamma radiation on the lipid profile of irradiated red blood cells.

    abstract::An investigation into the effects of irradiation and of the storage time on aging and quality are a relevant issue to ensure the safety and the efficiency of irradiation in the prevention of transfusion-associated graft-versus-host disease (TA-GVHD). In this work, the biochemical properties and alterations presented b...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-013-1944-5

    authors: Maia GA,Renó Cde O,Medina JM,Silveira AB,Mignaco JA,Atella GC,Cortes VF,Barbosa LA,Santos Hde L

    更新日期:2014-05-01 00:00:00

  • Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.

    abstract::The object of this study was to assess the estimation of 2- and 5-year overall survival and tumor response and the frequency and severity of treatment morbidity with a modified ProMACE-MOPP hybrid protocol in patients with primary CNS lymphoma (PCNSL). Thirty-two immunocompetent patients were treated with a regimen of...

    journal_title:Annals of hematology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00277-005-1005-9

    authors: Yamanaka R,Morii K,Shinbo Y,Takeuchi S,Tamura T,Hondoh H,Takahashi H,Onda K,Takahashi H,Tanaka R

    更新日期:2005-07-01 00:00:00

  • Genotyping of 22 blood group antigen polymorphisms and establishing a national recipient registry in the Korean population.

    abstract::It is often difficult for standard blood banks in Korea to supply adequate amounts of blood for patients with rare phenotype. Moreover, the definition of a blood in need is ambiguous, and much remains to be learned. In this study, we determined the prevalence of various red blood cell (RBC) antigens from a donor viewp...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-016-2645-7

    authors: Hong YJ,Chung Y,Hwang SM,Park JS,Kwon JR,Choi YS,Kim JN,Lee DH,Kwon SY,Cho NS,Song EY,Park KU,Song J,Han KS

    更新日期:2016-05-01 00:00:00

  • Toxoplasma gondii infection in patients with hematological malignancies.

    abstract::Toxoplasmosis is one of the most common parasitic infections in humans, but in most cases it does not cause serious illness; this protozoan can nevertheless cause devastating disease in immunocompromised hosts such as HIV-positive individuals. Only rarely is toxoplasmosis documented in hematological patients, and amon...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-004-0898-z

    authors: Pagano L,Trapè G,Putzulu R,Caramatti C,Picardi M,Nosari A,Cinieri S,Caira M,Del Favero A,GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto)-Infection Program.

    更新日期:2004-09-01 00:00:00

  • Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma.

    abstract::We analyzed the prognostic factors for a successful mobilization and peripheral blood stem cell collection in a series of 57 consecutive patients with multiple myeloma (MM); a new scoring system to predict an adequate mobilization in this subset of patients was also constructed. A total of 221 aphereses were performed...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s002770100351

    authors: Perea G,Sureda A,Martino R,Altés A,Martínez C,Cabezudo E,Amill B,Martín-Henao GA,González Y,Muñoz L,Peyret M,Brunet S,Sierra J

    更新日期:2001-10-01 00:00:00

  • The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion.

    abstract::Myelodysplastic syndromes (MDS) are hematopoietic stem cell malignancies associated with an erythroid maturation defect, resulting in anemia. Treatments for MDS include erythropoiesis-stimulating agents (ESAs). The identification of prognostic markers is important to help predict response and improve outcomes. Various...

    journal_title:Annals of hematology

    pub_type: 杂志文章,评审

    doi:10.1007/s00277-019-03799-4

    authors: Park S,Kelaidi C,Meunier M,Casadevall N,Gerds AT,Platzbecker U

    更新日期:2020-01-01 00:00:00

  • Acute megakaryoblastic leukaemia with extreme thrombocytosis and p190(bcr/abl)rearrangement.

    abstract::Acute megakaryoblastic leukaemia (AML-M7) is an uncommon disease, composing 0.5-1.2% of newly diagnosed adult acute myeloid leukaemias (AML). It is characterised by higher incidence and complexity of cytogenetic abnormalities. We report a rare case of Philadelphia (Ph) chromosome-positive AML-M7, presenting with extre...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-003-0783-1

    authors: Balatzenko G,Guenova M,Zechev J,Toshkov S

    更新日期:2004-06-01 00:00:00

  • The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.

    abstract::The prognostic value of peripheral blasts (PB) is not well-studied in patients with myelodysplastic syndromes (MDS). We evaluated the impact of PB on overall survival (OS) and transformation to acute myeloid leukemia (AML) in a large cohort. The MDS database at the Moffitt Cancer Center was retrospectively reviewed to...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-017-3186-4

    authors: Duong VH,Padron E,Al Ali NH,Lancet JE,Hall J,Kwok B,Zhang L,Epling-Burnette PK,List AF,Komrokji RS

    更新日期:2018-02-01 00:00:00

  • Diverse phenotypes and transfusion requirements due to interaction of β-thalassemias with triplicated α-globin genes.

    abstract::Co-inheritance of triplicated α-genes can alter the clinical and hematological phenotypes of β-thalassemias. We evaluated the phenotypic diversity and transfusion requirements in β-thalassemia heterozygotes, homozygotes, and normal individuals with associated α-gene triplication. Clinical and hematological evaluation ...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-015-2479-8

    authors: Mehta PR,Upadhye DS,Sawant PM,Gorivale MS,Nadkarni AH,Shanmukhaiah C,Ghosh K,Colah RB

    更新日期:2015-12-01 00:00:00